Cardiovascular Endocrinology & Metabolism最新文献

The association of polypharmacy with COVID-19 outcomes independent of comorbidities in people with type 2 diabetes: implications for the unforeseen consequences of polypharmacy 2型糖尿病患者的多重用药与COVID-19结果之间的关联（与合并症无关）：多重用药的不可预见后果的影响

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2024-05-23 DOI: 10.1097/XCE.0000000000000304

Juhi K. Gupta, Rathi Ravindrarajah, G. Tilston, Wiliam Ollier, Darren M. Ashcroft, Adrian H. Heald

引用次数: 0

Progress of uric acid in cardiovascular disease 尿酸在心血管疾病中的应用进展

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2024-04-12 DOI: 10.1097/XCE.0000000000000300

Tian-ming Gan, Yu-yu Ye, Guan-lian Mo, Jin-yi Li

引用次数: 0

Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure. 女性糖尿病合并严重心力衰竭患者乳酸酸中毒及酮症酸中毒1例。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2023-09-01 DOI: 10.1097/XCE.0000000000000287

Desire Nzomessi, Emmanuelle Massie, Karim Gariani, Raphael Giraud, Philippe Meyer

引用次数: 0

Takotsubo syndrome with several hypertensive crises: an unexpected diagnosis. Takotsubo综合征伴多例高血压危象:意外诊断。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2023-09-01 DOI: 10.1097/XCE.0000000000000291

Małgorzata Niemiec, Nicola Dyrek, Klaudia Żądecka, Bartosz Gruchlik, Adrianna Berger-Kucza, Katarzyna Mizia-Stec

引用次数: 0

First episode psychosis and weight gain a longitudinal perspective in Cheshire UK: a comparison between individuals with nonaffective versus affective psychosis. 英国柴郡首次发作精神病和体重增加的纵向视角:非情感性精神病与情感性精神病个体的比较。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2023-09-01 DOI: 10.1097/XCE.0000000000000286

Adrian H Heald, Mike Stedman, Chris Daly, John Julian Warner-Levy, Mark Livingston, Lamiece Hussain, Simon Anderson

{"title":"First episode psychosis and weight gain a longitudinal perspective in Cheshire UK: a comparison between individuals with nonaffective versus affective psychosis.","authors":"Adrian H Heald, Mike Stedman, Chris Daly, John Julian Warner-Levy, Mark Livingston, Lamiece Hussain, Simon Anderson","doi":"10.1097/XCE.0000000000000286","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000286","url":null,"abstract":"Early weight gain following initiation of antipsychotic treatment predicts longer-term weight gain, with attendant long-term consequences including premature cardiovascular events/death. An important question is whether there is a difference in weight change over time between people with affective versus nonaffective psychosis. Here we describe the results of a real-world analysis of the BMI change in the months postdiagnosis with affective versus nonaffective psychosis.Methods: We undertook an anonymised search across one Primary Care Network in Cheshire, UK with a total population of 32 301 individuals. We reviewed the health records of anyone who had been diagnosed over a 10-year period between June 2012 and June 2022 for the first time with first episode nonaffective psychosis versus psychosis associated with depression or bipolar affective disorder (affective psychosis).Results: The overall % change in BMI was +8% in nonaffective psychosis individuals and +4% in those with a diagnosis of affective psychosis - however, the distribution was markedly skewed for nonaffective psychosis patients. Using caseness as >30% increase in BMI; affective = 4% cases and nonaffective = 13% cases, there was a three-fold difference in terms of increase in BMI. In regression analysis, the r2 linking the initial BMI to % change in BMI was 0.13 for nonaffective psychosis and 0.14 for affective psychosis.Conclusion: The differences observed here in the distribution of weight change over time between individuals with affective versus nonaffective psychosis may relate to underlying constitutional differences. The phenotypic and genetic factors underlying this difference remain to be defined.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4e/73/xce-12-e0286.PMC10289689.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9714033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between right heart catheterization hemodynamics and glycosylated hemoglobin levels in adults with heart failure with reduced ejection fraction. 成人心力衰竭伴射血分数降低患者右心导管血流动力学与糖化血红蛋白水平的关系

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2023-09-01 DOI: 10.1097/XCE.0000000000000285

Gaspar Del Rio-Pertuz, Cristina Morataya, Kanak Parmar, Zeyad Elharabi, Daniel Davis, Mostafa Abohelwa, Ozman Ochoa, Alison Tran, Kenneth Nugent, David Paniagua, Erwin Argueta-Sosa

{"title":"Association between right heart catheterization hemodynamics and glycosylated hemoglobin levels in adults with heart failure with reduced ejection fraction.","authors":"Gaspar Del Rio-Pertuz, Cristina Morataya, Kanak Parmar, Zeyad Elharabi, Daniel Davis, Mostafa Abohelwa, Ozman Ochoa, Alison Tran, Kenneth Nugent, David Paniagua, Erwin Argueta-Sosa","doi":"10.1097/XCE.0000000000000285","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000285","url":null,"abstract":"This study hypothesized that elevated glycosylated hemoglobin (HbA1c) levels are associated with abnormal right heart catheterization (RHC) hemodynamic parameters in patients with heart failure with reduced ejection fraction (HFrEF) and no prior diagnosis of diabetes.Methods: Retrospective cohort study of adult patients with HFrEF and no prior diagnosis of diabetes who underwent RHC and had HbA1c levels measured 30 days before or after the RHC. This study excluded patients who had received blood transfusions within 90 days prior to HbA1c measurement and patients with known diabetes. Univariate and multivariate regression analyses adjusted for age, sex, and BMI were used to test for an association between RHC hemodynamic parameters and HbA1c levels.Results: A total of 136 patients were included with a mean age of 55 ± 15 years and mean HbA1c was 5.99 ± 0.64%. Unadjusted univariate models showed that HbA1c is significantly associated with cardiac index (CI) by the Fick method and thermodilution, right atrial pressure (RAP), and mean pulmonary arterial pressure (MPAP). After multivariate analysis, for every one unit increase in HbA1c, there was a 0.19 and 0.26 L/min/m2 decrease in expected CI by thermodilution and by the Fick method (P = 0.03 and P < 0.01), respectively. For every one unit increase in HbA1c, there was a 2.39 mmHg increase in expected RAP (P = 0.01).Conclusion: Elevated HbA1c levels measured within 30 days before or after the index RHC in patients with a left ventricular ejection fraction <40% were associated with congestive hemodynamic parameters.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9714037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mineralocorticoid receptor antagonists in cardiovascular translational biology. 钙皮质激素受体拮抗剂在心血管翻译生物学中的应用。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2023-09-01 DOI: 10.1097/XCE.0000000000000289

Robert J Chilton, José Silva-Cardoso

引用次数: 0

Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis. 钠-葡萄糖共转运蛋白-2抑制剂在2型糖尿病和其他心血管疾病危险因素患者中的安全性结局:一项系统回顾和荟萃分析

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2023-06-01 DOI: 10.1097/XCE.0000000000000284

Radhika Deshpande, Raj Patel, Manjari R Regmi, Mohsin Salih, Robert Kropp, Basma Al-Bast, Muhammad A Sheikh, Andrew Sagalov, Abhishek Kulkarni, Momin Siddique, Shruti Hegde, Mukul Bhattarai

{"title":"Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis.","authors":"Radhika Deshpande, Raj Patel, Manjari R Regmi, Mohsin Salih, Robert Kropp, Basma Al-Bast, Muhammad A Sheikh, Andrew Sagalov, Abhishek Kulkarni, Momin Siddique, Shruti Hegde, Mukul Bhattarai","doi":"10.1097/XCE.0000000000000284","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000284","url":null,"abstract":"Sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) have emerged as standard therapy for heart failure. We aim to assess the safety of SGLT2-Is in patients with a high risk of cardiovascular disease.Areas covered: An electronic database search was conducted for randomized control trials comparing SGLT2-Is to placebo in patients with a high risk of cardiac disease or heart failure. Data were pooled for outcomes using random-effect models. The odds ratio (OR) and 95% confidence interval (CI) were used to compare eight safety outcomes between the two groups. The analysis included ten studies with 71 553 participants, among whom 39 053 received SGLT2-Is; 28 809 were male and 15 655 were female (mean age, 65.2 years). The mean follow-up period was 2.3 years with the range being 0.8-4.2 years. The SGLT2-Is group had a significant reduction in AKI (OR = 0.8;95% CI 0.74-0.90) and serious adverse effects (OR = 0.9; 95% CI 0.83-0.96) as compared to placebo. No difference was found in fracture (OR = 1.1; 95% CI 0.91-1.24), amputation (OR = 1.1; 95% CI 1.00-1.29), hypoglycemia (OR 0.98;95% CI 0.83-1.15), and UTI (OR = 1.1; 95% CI 1.00-1.22). In contrast, DKA (OR = 2.4; 95% CI 1.65-3.60) and volume depletion (OR = 1.2; 95% CI 1.07-1.41) were higher in SGLT2-Is group.Expert opinion/commentary: The benefits of SLGT2-Is outweigh the risk of adverse events. They may reduce the risk of AKI but are associated with an increased risk of DKA and volume depletion. Further studies are warranted to monitor a wider range of safety outcomes of SGLT2-Is.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9467679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Enhancing type 2 diabetes treatment through digital plans of care. Patterns of access to a care-planning app over the first 3 months of a digital health intervention. 通过数字化护理计划加强2型糖尿病的治疗。在数字健康干预的前三个月里，使用护理计划应用程序的模式。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2023-06-01 DOI: 10.1097/XCE.0000000000000283

Adrian H Heald, Sarah Roberts, Lucia Albeda Gimeno, John Martin Gibson, Anuj Saboo, Jonathan Abraham

引用次数: 1

Association between right heart catheterization hemodynamics and glycosylated hemoglobin levels in adults with heart failure with reduced ejection fraction 射血分数降低的心力衰竭成人右心导管血流动力学与糖化血红蛋白水平的相关性

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2023-04-01 DOI: 10.1016/j.cardfail.2022.10.263

G. Del Rio-Pertuz, C. Morataya, K. Parmar, Z. Elharabi, Daniel Davis, Mostafa M Abohelwa, Ozman Ochoa, Alison Tran, K. Nugent, D. Paniagua, Erwin E Argueta-Sosa

引用次数: 0